Save

VIDEO: Entyvio shows superiority in ulcerative colitis

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on . Please provide your email address to receive an email when new articles are posted on Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts



Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.



Back to Healio

SAN DIEGO — In this exclusive video from Digestive Disease Week, Bruce Sands, MD, from Icahn School of Medicine at Mount Sinai, discusses findings from the VARSITY study, the first head-to-head trial comparing biologic therapies for ulcerative colitis.

“We were comparing adalimumab [Humira, AbbVie], an anti-TNF antibody, to vedolizumab [Entyvio, Takeda], which is an anti-alpha 4 beta 7 integrin antibody, in patients with ulcerative colitis,” Sands told Healio Gastroenterology and Liver Disease. “These are two widely used treatments for ulcerative colitis, but the two have never been compared head-to-head in a randomized controlled fashion.”

The VARSITY study was a 52-week double-dummy, blinded study. Earlier this year, Sands presented Data that showed vedolizumab was superior in terms of achieving clinical remission at week 52.

At DDW, Sands presented additional data on histologic remission at week 52. Histologic outcomes were also superior in vedolizumab.

“We think this is an important study,” Sands said. “It helps us understand where to position these drugs in relation to each other.”

Reference:

Sands BE, et al. Abstract 426a. Presented at: Digestive Disease Week; May 18-21, 2019; San Diego.

Disclosure: Sands reports financial support for research from Celgene, Janssen, Pfizer and Takeda.